Results 151 to 160 of about 2,052,688 (283)

From pathogen to “living drug factory” innovative strategies and clinical translation of bacteria as programmable intelligent vectors for cancer therapy

BMEMat, EarlyView.
Engineered bacteria serve as smart, living therapeutics that target tumors, deliver drugs, and remodel immunosuppressive microenvironments. This review highlights their potential to potentiate immunotherapy, radiotherapy, and chemotherapy, offering a promising paradigm for precise and synergistic cancer treatment. Abstract The dynamic interplay between
Haonan Shen, Weichen Zhang, Gaoli Niu, Li Wang, Ruiyan Li, Yueyue Fan, Feixue Lu, Lingling Xu, Xiaoyuan Ji, Yong Kang   +9 more
wiley   +1 more source

Advancing In Vivo Chimeric Antigen Receptor T-Cell Engineering to Accelerate Clinical Translation. [PDF]

MedComm (2020)
Bai Z, Yi M, Hu S, Xue D, Wei L, Zhang L, Dai Z.   +6 more
europepmc   +1 more source

Defect‐engineered tungsten oxide nanowires as redox‐metabolic nanozymes for gut inflammation‐infection syndromes

BMEMat, EarlyView.
Defect‐engineered WO3 nanowires serve as a multifunctional nanozyme platform to treat IBD complicated by Salmonella co‐infection. By integrating catalytic ROS/RNS scavenging and targeted metabolic interference of pathogens via molybdenum substitution, these nanowires effectively resolve intestinal oxidative stress, inhibit infection, and restore ...
Yifan Yuan, Shipeng Zhang, Mingxuan Liu, Xurui Hou, Yizhi Dai, Weiyu Zhang, Zhongwei Yang, Xiaoyu Zhang, Jiahui Mao, Mingge Wang, Xin Yang, Ping Zhang, Hui Wang, Jing Liu   +13 more
wiley   +1 more source

The carbon footprint of Chimeric Antigen Receptor-T cell manufacturing processes. [PDF]

Int J Pharm X
van der Bijl WE, Gareb B, Klomberg KM, Bremer E, van Meerten T, Oude Munnink TH, Dekkers BGJ.   +6 more
europepmc   +1 more source

The Multiple Criteria Qualitative Value‐Based Pricing Framework “MARIE” for Novel Cell and Gene Therapy

Clinical Pharmacology &Therapeutics, EarlyView.
When setting the price of cell and gene therapies in Japan, the factors considered include the manufacturing and operating costs of the new drug or a comparator, leading to discrepancies between price and values, in particular those specific to cell and gene therapies.
Akina Takami, Ataru Igarashi
wiley   +1 more source

Flow cytometry‐based monitoring of chimeric antigen receptor (CAR) T cells: Reagent selection, assay design, and clinical utility

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Accurate quantification of chimeric antigen receptor (CAR) T cells is essential for monitoring post‐infusion CART expansion and persistence and for real‐time clinical decision‐making. Multiparameter flow cytometry (MFC) enables rapid, live‐cell detection with absolute quantification and concurrent immunophenotypic characterization. This review
Jianhua Ling, Wei Wang, Sa A. Wang
wiley   +1 more source

Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases. [PDF]

Signal Transduct Target Ther
Fan Z, Zheng X, Jin C, Zhang J, Gong N, Li X.   +5 more
europepmc   +1 more source

Goofy/123Cre lineage tracing differentiates olfactory and vomeronasal neurons from GnRH‐1 and terminal nerve neurons during neuronal migration and reveals additional olfactory placode‐derived cells in the brain

Developmental Dynamics, EarlyView.
Abstract The olfactory placode (OP) generates a broad array of chemosensory neurons in the nasal region, including olfactory sensory neurons, vomeronasal sensory neurons, neurons of the septal organ, and Grueneberg ganglion. During invagination, the OP also generates migratory neuronal populations, including gonadotropin‐releasing hormone‐1 (GnRH‐1 ...
Enrico Amato Jr., Mia V. Call, Noah M. LeFever, Mya Aviles‐Carlos, Nikki M. Dolphin, Paolo E. Forni   +5 more
wiley   +1 more source

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler, Friederike Zimmermann, Bettina Heidecker, Ulf Landmesser, Arash Haghikia   +4 more
wiley   +1 more source

Could chimeric antigen receptor-T cell treatment of atherosclerosis in mice translate to a human therapy? [PDF]

Ann Transl Med
Gieseg S, Hock B, Ogugofor M, McCormick S.   +3 more
europepmc   +1 more source